[1]陈晓铭 胡卓清 李潍 刘美莲 吴美芬 方烁 武革.CD40-1C/T多态性（rs1883832）与粤西汉族人Graves病的关系[J].国际内分泌代谢杂志,2015,(01):11-15.[doi:10.3760/cma.j.issn.1673-4157.2015.01.003]
　Chen Xiaoming,Hu Zhuoqing,Li Wei,et al.Relationship between CD40-1C/T polymorphism（rs1883832）and Graves′ disease of Han population in western region of Guangdong province[J].International Journal of Endocrinology and Metabolism,2015,(01):11-15.[doi:10.3760/cma.j.issn.1673-4157.2015.01.003]
点击复制

CD40-1C/T多态性（rs1883832）与粤西汉族人Graves病的关系()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
期数:
2015年01
页码:
11-15
栏目:
论著
出版日期:
2015-01-20

文章信息/Info

Title:
Relationship between CD40-1C/T polymorphism（rs1883832）and Graves′ disease of Han population in western region of Guangdong province
作者:
陈晓铭 胡卓清 李潍 刘美莲 吴美芬 方烁 武革
524001湛江，广东医学院附属医院内分泌科
Author(s):
Chen Xiaoming; Hu Zhuoqing; Li Wei; Liu Meilian; Wu Meifen; Fang Shuo; Wu Ge.
Department of Endocrinology,Affiliated Hospital of Guangdong Medical College, Zhanjiang 524001,China Corresponding author: Wu Ge, Email:wuge427@aliyun.com
关键词:
Graves病; CD40; 基因多态性
Keywords:
Graves disease; CD40; Gene polymorphisms
DOI:
10.3760/cma.j.issn.1673-4157.2015.01.003
摘要:
目的 探讨CD40基因单核苷酸多态性(rs1883832)与粤西汉族人群Graves病的关系。 方法 选取Graves病患者219例(Graves病组)和健康体检人员200例（对照组）。收集相关资料，检测甲状腺激素(游离T3、游离T4)、促甲状腺激素（TSH）及促甲状腺激素受体抗体（TRAb）水平。应用聚合酶链反应限制性片段长度多态性（PCRRFLP）对样本基因分型。分析基因多态性与Graves病遗传易感性、家族史、眼病和预后的关系，及TRAb水平在不同基因型携带者之间的差异。结果（1）Graves病组等位基因C分布频率高于对照组（56.8% vs. 47.3%，χ2=7.722, P=0.005）；共性及隐性遗传模型均显示Graves病组CC基因型高于对照组（38.4%vs. 25.5%，χ2=8.054,P共性=0.018;χ2=7.912,P隐性=0.005）；相对于等位基因T携带者，CC基因型增加Graves病发病风险［CC vs. TT：优势比（OR）=1.89，CC vs. CT：OR=1.77，CC vs. CT+TT： OR=1.83）。（2）等位基因与基因型分布频率在有/无家族史、伴/不伴眼病及初发/复发亚组中差异均无统计学意义（P均＞0.05）。（3）在Graves病组中，C等位基因携带者TRAb水平较TT基因型者高［（18.23±0.96）vs.（12.65±1.68）IU/L，F=4.576，P=0.002］。 结论 CD40-1C/T多态性（rs1883832）可能与粤西汉族人群 Graves病及TRAb水平相关，与甲状腺眼病、家族史及预后无关。
Abstract:
Objective To investigate the association between the single nucleotide polymorphism(SNP, rs1883832) of CD40 gene and Graves′disease(GD) of Han population in western Guangdong. Methods A set of subjects including 219 patients with GD (GD group) and 200 healthy controls(control group) were recruited.Related informations were collected, and levels of thyroid hormones (free T3,free T4), thyroid stimulating hormone (TSH) and thyrotropin receptor antibodies（TRAb) were tested. SNPs were genotyped by the method of polymerase chain reactionrestriction fragment length polymorphism (PCR-RFLP).The association between polymorphism and the susceptibility of GD,family history,ophthalmopathy and prognosis of GD were analyzed.Meanwhile, the levels of TRAb among different genotypes were compared. Results（1）Higher allele C frequency was observed in GD group than control group(56.8%vs.47.3%,χ2=7.722,P=0.005).Compared with control group,additive and recessive genetic models showed the frequency of CC genotype were higher in GD group (38.4% vs.25.5%,χ2=8.054, P Additive=0.018;χ2=7.912, P Ressive=0.005).Compared with patients carried allele T, GD risk of the individuals who carried CC genotype was significantly increased[CC vs. TT:odd ratio (OR)= 1.89, CC vs.CT: OR=1.77,CC vs.CT+TT:OR=1.83].（2）There was no significant difference in allele or genotype frequency of CD40 SNP between patients with and without GD family history, with and without ophthalmopathy, GD onset and relapse subgroup(all P＞0.05). （3）In GD group, the levels of TRAb were significant higher in those with CC or CT genotype than other genotype[（18.23±0.96) vs.(12.65±1.68)IU/L,F=4.576,P=0.002].Conclusion CD40-1C/Tpolymorphism （rs1883832） is associated with GD and TRAb level of Han population in western Guangdong. No correlation is found between CD40-1C/T polymorphism and ophthalmopathy, family history and prognosis of GD.

参考文献/References:


[1]Brix TH, Kyvik KO, Christensen K, et al. Evidence for a major role of heredity in Graves′disease:a population based study of two Danish twin cohorts[J]. J Clin Endocrinol Metab,2001,86(2):930-934.
[2]Balazs C.The role of hereditary and environment factors in autoimmune thyroid disease[J].Orv Hetil,2012,153(26):1013-1022.
[3]Jacobson EM, Huber AK, Akeno N, et al.A CD40 Kozak sequence polymorphism and susceptibility to antibody mediated autoimmune conditions:the role of CD40 tissue specific expression[J].Genes Immun,2007,8(3):205-214.
[4]吴砂.免疫细胞膜分子//龚非力，主编.医学免疫学[M].第3版.北京:科学出版社,2012:69-72.
[5]Yang J, Qin Q, Yan N, et al. CD40 C/T(-1) and CTLA-4 A/G(49) SNPs are associated with autoimmune thyroid diseases in the Chinese population[J]. Endocrine,2012,41(1):111-115.
[6]王海宁，江鹤，刘威，等.在中国汉族人群中CD40 5′非翻译区的SNP与Graves病相关∥中华医学会第十二次全国内分泌学学术会议论文汇编，西安，2013[C].2013:119.
[7]Tomer Y, Ban Y, Concepcion G, et al.Common and unique susceptibility loci in Graves′and Hashimoto′s disease: results of whole genome screening in a data set of 102 multiplex families[J]. Am J Hun Genet,2003,73(4):736-747.
[8]滕卫平，甲状腺功能亢进症//葛均波，徐永健，主编.内科学[M].第8版.北京：人民卫生出版社,2013:685-692.
[9]Smith TJ, Sciaky D, Phipps RP, et al. CD40 expression in human thyroid tissue: evidence for involvement of multiple cell types in autoimmune and neoplastic diseases[J].Thyoid,1999,9(8):749-755.
[10]Jacobson EM, Concepcion E, Oashi T, et al. A Graves′diseaseassociated Kozak sequence singlenucleotide polymorphism enhance the efficiency of CD40 gene translation: a case for translational pathophysiology[J].Endocrinology,2005,146(6):2684-2691.
[11]Hsiao JY, Tien KJ, Hsiao CT, et al.A C/T polymorphism in CD40 gene is not associated with susceptibility and phenotype of Graves′disease in Taiwanese[J].Endocr J,2008,55(3):477-484.
[12]孙玲玲，褚讯，黄薇，等.CD40基因多态性与Graves病的相关性研究[J].实用医学杂志,2007,23(5):655-657.
[13]马利丹，阎胜利，李鹏，等.CD40基因5′非翻译区-1位点C/T多态性与Graves病药物治疗停药后复发的相关性[J].免疫学杂志,2010,26(6):517-520,526.
[14]Wang PW,Chen IY,Juo SH,et al.Genotype and phenotype predictors of relapse of Graves′ disease after antithyroid drug withdrawal[J].Eur Thyroid J,2013,1(4):251-258.
[15]Huber AK,Finkelman FD,Li CW,et al. Genetically driven target tissue overexpression of CD40: a novel mechanism in autoimmune disease[J].J Immunol,2012,189(6):3043-3053.

相似文献/References:

[1]赵永强,田德增,魏晓华,等.不同治疗方法对Graves病患者外周血淋巴细胞亚群的影响[J].国际内分泌代谢杂志,2015,(04):234.[doi:10.3760/cma.j.issn.1673-4157.2015.04.005]
　Zhao Yongqiang*,Tian Dezeng,Wei Xiaohua,et al.Effects of different therapeutic methods on peripheral blood lymphocyte subgroups in patients with Graves' disease[J].International Journal of Endocrinology and Metabolism,2015,(01):234.[doi:10.3760/cma.j.issn.1673-4157.2015.04.005]
[2]瞿茹怡,李圣贤,陆咏,等.2q33区基因多态性与Graves病发病风险的研究[J].国际内分泌代谢杂志,2014,(02):77.[doi:10.3760/cma.j.issn.1673-4157.2014.02.002]
　Qu Ruyi*,Li Shengxian,Lu Yong,et al.Association between 2q33 gene polymorphism and Graves' disease[J].International Journal of Endocrinology and Metabolism,2014,(01):77.[doi:10.3760/cma.j.issn.1673-4157.2014.02.002]
[3]朱萍,卫红艳,王坤玲,等.Graves病甲状腺功能亢进症性肝损害的 相关因素分析[J].国际内分泌代谢杂志,2017,37(03):164.[doi:10.3760/cma.j.issn.1673-4157.2017.03.005]
　Zhu Ping,Wei Hongyan,Wang Kunling,et al.Related factors of hyperthyroidism-related liver dysfunction in Graves' disease[J].International Journal of Endocrinology and Metabolism,2017,37(01):164.[doi:10.3760/cma.j.issn.1673-4157.2017.03.005]
[4]马金刚 魏红丽 尚恒.Graves病患者外周血T细胞亚群与甲状腺 功能及甲状腺自身抗体间的相关性分析[J].国际内分泌代谢杂志,2020,40(01):21.[doi:10.3760/cma.j.issn.1673-4157.2020.01.005]
　Ma Jingang,Wei Hongli,Shang Heng.Correlation between peripheral blood T cell subsets and thyroid function and thyroid autoantibodies in patients with Graves' disease[J].International Journal of Endocrinology and Metabolism,2020,40(01):21.[doi:10.3760/cma.j.issn.1673-4157.2020.01.005]
[5]陈莹 倪文婧 陈国芳 徐书杭.基于复发危险因素探讨Graves病治疗的新策略[J].国际内分泌代谢杂志,2022,42(04):260.[doi:10.3760/cma.j.cn121383-20210412-04031]
　Chen Ying,Ni Wenjing,Chen Guofang,et al.New strategies for the treatment of Graves' disease based on risk factors of relapse[J].International Journal of Endocrinology and Metabolism,2022,42(01):260.[doi:10.3760/cma.j.cn121383-20210412-04031]
[6]陈莹 徐书杭.2022年欧洲甲状腺学会《儿童Graves病管理指南》解读[J].国际内分泌代谢杂志,2023,43(05):449.[doi:10.3760/cma.j.cn121383-20220629-06064]
　Chen Ying,Xu Shuhang.Interpretation of 2022 European Thyroid Association Guideline for the management of pediatric Graves' disease[J].International Journal of Endocrinology and Metabolism,2023,43(01):449.[doi:10.3760/cma.j.cn121383-20220629-06064]

备注/Memo

备注/Memo:
（收稿日期：2014-07-14）
更新日期/Last Update: 2015-03-20